AstraZeneca and Myriad Genetics are partnering to identify women with advanced ovarian cancer who might benefit from treatments using Lynparza and Avastin as part of a phase 3 trial.
Under the partnership, Myriad’s myChoice HRD Plus test will be used to identify patients already enrolled in the trial who have homologous recombination deficiencies (HRD). Financial terms of the agreement weren’t disclosed.
“MyChoice HRD Plus is the most comprehensive test for identifying defects in DNA repair pathways,” Jerry Lanchbury, Ph.D., chief scientific officer for Myriad, said in a statement. “We are optimistic that myChoice HRD Plus will identify more women with ovarian cancer who could benefit from therapy with Lynparza than previous tests that only identify germline BRCA1/2 mutations.”
The two companies have been working together since 2007 when they teamed to develop a companion diagnostic test to identify candidates for treatment with olaparib. Four years ago, Myriad got the FDA nod for its BRACAnalysis CDx to identify patients with advanced ovarian cancer who are eligible for fourth-line treatment with olaparib. BRACAnalysis CDx was the first-ever laboratory-developed test approved by the regulatory agency.
In November, Myriad announced it partnered with CareFirst BlueCross BlueShield to evaluate a multibiomarker rheumatoid arthritis blood test. The 18-month study will assess whether Vectra DA delivers better outcomes and lower costs than conventional approaches.